The U.S. pharmaceutical excipients market size surpassed USD 2.58 billion in 2025 and is predicted to reach around USD 5.12 billion by 2035, registering a CAGR of 7.1% from 2026 to 2035. The modernized drug delivery systems and convenient patient-centric formulations are bolstering the regional market growth.

U.S. Pharmaceutical Excipients Market Statical Scope

The businesses in the regional market are sustaining with the sustained related formulations that attract more engagement from the brand-name drugs. The motivation for the multifunctional excipients is fuelling more confidence in the regional market business. While the expansion of the biopharmaceuticals sector is accelerating the demand for the stabilizers, as the efficacy of the high-purity excipients is essential.

U.S. Pharmaceutical Excipients Market Share, By Product, 2025 (%)

• Organic Chemicals – The organic chemicals segment dominated the market by 69% of share, as the sound dominance of the plant-based materials in the market is serving high income to the segmental market. The extensive biopharmaceutical portfolio is bolstering the segment growth in healthcare.
• Inorganic Chemicals – The segment covers 31% of the share, as extending the queue of drug delivery is welcoming the high-purity excipients to cooperate with the vast regional healthcare sector. The segment proves its potential in the tablet manufacturing site.

U.S. Pharmaceutical Excipients Market Share, By Functionality, 2025 (%)

• Fillers and Diluents – The fillers and diluents segment covers 23% of the share with the robust grip of small molecule formulation that allows accurate dosing. The solid dosage demand and supply are ringing with the segments' fame in the market.
• Binders – The binders segment leads by 14% of the share, as a multifunctional approach is in demand that improves formulation efficiency. The innovative binder solutions in biologics are promoting balance and compatibility.
• Coatings (Film and Enteric) – The segment covers 12% of the share with the rising focus on aesthetics that is now beyond this meeting specialized, enteric or functional coatings . The advancement perk is strengthening the segmental market growth.
• Suspension and Viscosity Agents – The segment leads by 11% of the share as the organic ingredients are undergoing commendable transitions for the required success in clean label. The perfect content to avoid settling is the flowing growth in the segmental market.

U.S. Pharmaceutical Excipients Market Share, By Formulation, 2025 (%)

• Oral Solid Dosage Forms – The segment acquires 46% of the share as the famous patient-centric formulation is attracting the establishment of the excipients. The rising geriatric and pediatric populations are the customers for this formulation.
• Parenteral Formulations – The parenteral formulations segment covers 18% of the profit, with the rising demand for parenteral (injectable) therapies that centralize the need for effective excipients to achieve accuracy.
• Topical and Transdermal – The segment acquires 14% of the share with the impressive modern dermatology treatments that attract businesses via heavy production of ointments, creams and gel. The iontophoresis technologies and nanoparticle-infused creams are a tech advancement for the market.
• Pulmonary/Inhalation – The segment rises by 9% of the share due to the remarkable performance of DPI technologies, mainly for the oral/injection alternative. Following this, the role of specialized carrier-free and carrier-based excipients is promoting the capacity of the segmental market.

U.S. Pharmaceutical Excipients Market Share, By Source, 2025 (%)

• Plant-based – The plant-based segment acquires 32% of the share as the famous demand for clean, green, sustainable, animal-free alternatives brought the segment's potential into the limelight. The use of xanthan gum, coconut oil and olive oil is elevating the segmental market strength.
• Synthetic – The segment leads by 30% of the share as synthetic lipids are contributing effectively to the liposomal drug delivery, vaccines and RNA therapeutics. The utilization of multifunctional excipients is stimulating the market growth.
• Mineral-based – The segment covers 20% of the share as mineral alternatives are in popular demand for the making of calcium carbonate. The refining of tablet production is accompanied by the mineral salts expands the segmental market.
• Animal-based – The segment held 18% of the share with the massive use of lactose as a binder and filler for oral tablets. The soft/hard capsules' dominance is driven by a skin and health-conscious population.

Top Companies in the U.S. Pharmaceutical Excipients Market

• BASF SE
• Ashland Global Holdings Inc.
• DuPont de Nemours Inc.
• Roquette Frères SA
• Evonik Industries AG
• Archer Daniels Midland Co.
• Kerry Group plc
• The Lubrizol Corporation
• Air Liquide SA
• Croda International plc
• Innophos Holdings Inc.
• Colorcon Inc.
• DFE Pharma GmbH & Co. KG
• JRS Pharma GmbH & Co. KG
• Eastman Chemical Company
• International Flavors & Fragrances Inc.
• Merck KGaA
• Dow Inc.
• Gattefossé SA
• Shin-Etsu Chemical Co. Ltd.

Segments Covered in the Report

By Product

• Organic Chemicals
• Inorganic Chemicals

By Functionality

• Fillers & Diluents
• Binders
• Suspension and Viscosity Agents
• Coatings (Film & Enteric)
• Flavoring Agents
• Disintegrants
• Colorants
• Preservatives
• Other Functionalities

By Formulation

• Oral Solid Dosage Forms
• Parenteral Formulations
• Topical & Transdermal
• Pulmonary/Inhalation
• Ophthalmic
• Others (Sublingual, Buccal, etc.)

By Source

• Plant-based
• Animal-based
• Synthetic
• Mineral-based
• Marine-based